March 28th, 2014
ACC.14 Headquarters
wpengine
CardioExchange is dedicated to bringing you the latest from ACC.14. Check out our coverage of the conference ─ and some of the great debates these posts have sparked ─ then tell us what you think!
News:
Analysis:
Follow our Fellows:
NEJM — Recent Cardiology Articles- Survodutide Once Weekly for the Treatment of Adults with Obesity August 20, 2026In a phase 3 trial involving adults with obesity but without diabetes, the glucagon receptor–GLP-1 receptor dual agonist survodutide led to significantly greater reductions in body weight than placebo.
- The Broader Dangers of Abandoning SGM Health Research August 20, 2026When research is defunded not for scientific reasons but because it has become politically inconvenient, the ensuing damage is wide ranging, affecting far more than the disfavored topics and populations.
- A New Approach to Lowering LDL Cholesterol August 13, 2026The pioneering work of Vafai and colleagues, reported in this issue of the Journal,1 paves the way for a new type of low-density lipoprotein (LDL) cholesterol–lowering therapy called VERVE-102: a therapy that appears to lower LDL cholesterol levels enough to reduce the risk of atherosclerotic cardiovascular...
- Last Man Running August 13, 2026As the health of his brother and running buddy rapidly declines and he faces his own health scares, a physician feels compelled — and grateful — to keep moving forward.
- In Vivo Base Editing of PCSK9 with VERVE-102 for Hypercholesterolemia August 13, 2026The authors report reductions in PCSK9 and LDL cholesterol levels and no dose-limiting toxic effects in persons with hypercholesterolemia treated with VERVE-102, a base editor targeting PCSK9.
- Survodutide Once Weekly for the Treatment of Adults with Obesity August 20, 2026